Table 1

Demographic, clinical, and laboratory data of the methotrexate study cohort

Characteristics of cohort

Value

Number of patients

13

Median age (range), years

56 (32-78)

Number of males/females

4/9

Median interval from diagnosis (range), days

7 (1-25)

Median duration of symptoms (range), months

6.5 (2-12)

ACPA-positive patients, number (percentage)

6 (46)

Rheumatoid factor-positive patients, number (percentage)

9 (69)

Number of patients taking oral corticosteroids

2

Number of patients taking NSAIDs

10

Median duration between biopsies (range), days

58 (45-70)

Number of patients presenting erosions (percentage)

At baseline

2 (15)

After 1 year

7 (53)

Mean DAS28 (minimum, maximum)

At baseline

5.7 (3.9, 6.7)

After 3 months

3.8 (1.8, 5.8)

ACPA, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; NSAID, non-steroidal anti-inflammatory drug.

Gheorghe et al. Arthritis Research & Therapy 2012 14:R121   doi:10.1186/ar3851